Stockreport

Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Jade Biosciences, Inc.  (JBIO) 
PDF JADE101 Phase 1 healthy volunteer interim data expected in the second quarter of 2026; Phase 2 clinical trial in patients with IgA nephropathy expected to begin mid-2026 [Read more]